公司资料
Biogen 股价、新闻与催化剂
- 股票代码:
- BIIB
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
222.82 USD (-1.35%)
收盘价
最后更新: 2026年10月1日
27.9B USD
市值
股价为何变动
最新监测到的公司动态为“Biogen’s Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Thera…”。相应的收盘价反应尚未产生。
公司概览
业务概览
Biogen is a large biotechnology company focused on neuroscience and rare disease, with a long history in multiple sclerosis and other neurological disorders. Its business combines commercial products with a major research engine.
所在地与行业分类
Biogen is headquartered in the United States and listed on NASDAQ. It sits in large-cap biotechnology with a neuroscience identity.
商业模式特征
The company generates value through product sales, lifecycle management, and ongoing R&D in difficult CNS and rare-disease areas. Investors watch launch execution, pipeline progress, and franchise durability.
生物医药行业定位
Biogen occupies one of the most important large-cap neuroscience positions in biotech. It is far less binary than a small-cap name, but major pipeline and label events still matter a lot.
未来催化剂
- Biogen’s catalysts are lecanemab execution, rare-disease growth, and any CNS pipeline update that helps extend the franchise. The market will watch whether the commercial base keeps broadening.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。